YBGJ (Yubo International Biotech) Altman Z2-Score: -70.70 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Yubo International Biotech Altman Z2-Score?

Yubo International Biotech YBGJ +21.21% Altman Z2-Score is -70.70 as of Jul. 14, 2026. The stock has 2 warning signs investors should review. Among 844 Medical Devices & Instruments companies, Yubo International Biotech ranks worse than 95.26% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Yubo International Biotech has a Altman Z2-Score of -70.70, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Yubo International Biotech's Altman Z2-Score or its related term are showing as below:

YBGJ' s Altman Z2-Score Range Over the Past 10 Years
Min: -70.7   Med: -17.65   Max: -0.69
Current: -70.7

During the past 6 years, Yubo International Biotech's highest Altman Z2-Score was -0.69. The lowest was -70.70. And the median was -17.65.


Yubo International Biotech  (OTCPK:YBGJ) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Yubo International Biotech Altman Z2-Score Related Terms


Yubo International Biotech Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech Altman Z2-Score Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial -6.52 -13.72 -25.43 -40.83 -57.39

Yubo International Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.44 -61.57 -49.11 -57.39 -70.70

YBGJ vs GCTK, ECIA, RSCF: Altman Z2-Score Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yubo International Biotech Altman Z2-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Altman Z2-Score falls into.



Yubo International Biotech Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Yubo International Biotech's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-3.4099+3.26*-11.2859+6.72*-1.5986+1.05*-0.7612
=-70.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $0.71 Mil.
Total Current Assets was $0.60 Mil.
Total Current Liabilities was $3.02 Mil.
Retained Earnings was $-8.01 Mil.
Pre-Tax Income was -0.295 + -0.286 + -0.31 + -0.25 = $-1.14 Mil.
Interest Expense was -0.006 + 0 + 0 + 0 = $-0.01 Mil.
Total Liabilities was $3.02 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.598 - 3.019)/0.71
=-3.4099

X2=Retained Earnings/Total Assets
=-8.013/0.71
=-11.2859

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-1.141 - -0.006)/0.71
=-1.5986

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-2.298 - 0)/3.019
=-0.7612

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Yubo International Biotech has a Altman Z2-Score of -70.70 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -70.70 mean?
Yubo International Biotech (YBGJ) has a Altman Z2-Score of -70.70 as of Jul. 14, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Yubo International Biotech and its competitors. According to the industry distribution chart, Yubo International Biotech ranks #804 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 95.3%.
Is Yubo International Biotech's Altman Z2-Score too high?
Yubo International Biotech's current Altman Z2-Score is -70.70. Based on the distribution chart, Yubo International Biotech ranks #804 out of 844 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Yubo International Biotech's Altman Z2-Score compare to GCTK and ECIA?
According to the Medical Devices & Instruments industry distribution chart, Yubo International Biotech ranks #804 out of 844 companies for Altman Z2-Score. This places Yubo International Biotech in the lower half of its industry. The industry median Altman Z2-Score is 3.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.49, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Yubo International Biotech and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yubo International Biotech's current Altman Z2-Score is -70.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current Altman Z2-Score of -70.70. The current Altman Z2-Score is -70.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current Altman Z2-Score is -70.70 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.